Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT05413200 Completed - Acne Vulgaris Clinical Trials

Investigation of the Effect of Oral Isotretinoin on Skin Thickness and Elasticity in Patients With Atrophic Acne Scar

Start date: November 1, 2021
Phase:
Study type: Observational [Patient Registry]

Acne scar is a common complication of acne vulgaris (AV). Early and effective treatment of AV has a crucial role in managing both acne and acne scarring. Oral isotretinoin (OI) is a widely preferred agent in treating moderate and severe AV worldwide. It has been shown that topical retinoids can also be effective in the treatment of atrophic acne scars. However, there is no study in the literature evaluating the effectiveness of OI protocol on atrophic scars with objective data. With the developing sonoelastography technology in recent years, a quantitative, objective, and reliable examination of the elasticity of the skin and subcutaneous tissue can be provided. In this study, for a detailed and objective evaluation of the effects of OI on atrophic acne scars, we investigate the AV severity, atrophic scar grade, scar size (SS), dermis and subcutaneous tissue thickness (STT), and changes in scar and subcutaneous tissue elastic modulus (EM) in moderate and severe AV patients with atrophic acne scars by clinical observation and SWE. Materials and Methods: It was designed as a single-center, prospective and observational study. Ethics committee approval was obtained. Thirty patients who applied to the Istanbul Training and Research Hospital, Dermatology Department, between November 2021 and January 2022 diagnosed with moderate and severe AV accompanied by atrophic acne scars were included in the study. Demographic characteristics of the patients were recorded. We started the OI with a standard dose regime. On days 0 and 90 of treatment, each patient's AV and scar severity; were evaluated with the global acne grading system (GAGS) and the Goodman and Baron Qualitative Global Scar Rating System (GSRS). On the same days, the dermal thickness (DT), STT, SS, scar, and subcutaneous tissue EM on the right and left cheeks were measured by the same experienced radiologist with SWE. Appropriate statistical methods analyzed the results.

NCT ID: NCT05399290 Completed - Acne Vulgaris Clinical Trials

Subantimicrobial Doxycycline in Acne

Start date: November 19, 2020
Phase: Phase 4
Study type: Interventional

Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, clinicians can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. The investigators aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.

NCT ID: NCT05398939 Completed - COVID-19 Clinical Trials

Impact of COVID-19 Vaccination on Serum 25-hydroxyvitamin D Level

Start date: May 25, 2022
Phase:
Study type: Observational

Vitamin D plays a pivotal but still not well understood role in the immune response to coronavirus disease (COVID-19) infection and vaccination. Many studies also showed a high negative correlation between the severity of inflammatory disease and serum 25-hydroxyvitamin D levels. Patients with acne vulgaris often had deteriorated skin condition after COVID-19 vaccination. Therefore, this study aimed to investigate the relationship of COVID-19 vaccination with serum 25-hydroxyvitamin D level and severity of acne vulgaris.

NCT ID: NCT05358860 Completed - Clinical trials for Acne Scars - Mixed Atrophic and Hypertrophic

Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.

NCT ID: NCT05345093 Completed - Acne Vulgaris Clinical Trials

Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis

Start date: November 11, 2022
Phase: N/A
Study type: Interventional

The Research Question of the present study is the following: in a population of men and women affected by acne vulgaris, and folliculitis, will Ialuxid® Gel (hydrogen peroxide, hyaluronic acid and glycine) improve the course of the disease, resulting in a decrease of the total number of lesions, results observed after 4 and 8 weeks after the beginning of the treatment?

NCT ID: NCT05316675 Not yet recruiting - Acne Vulgaris Clinical Trials

Impact of Isotretinoin in Different Doses on Quality of Life

Start date: December 2022
Phase: Phase 4
Study type: Interventional

The Cardiff Acne Disability Index is a short five-item questionnaire derived from the longer Acne Disability Index.It is designed for use in teenagers and young adults with acne. It is self explanatory and can be simply handed to the patient who is asked to complete it without the need for detailed explanation( .Abdelrazik etal., 2021). .

NCT ID: NCT05301569 Recruiting - Clinical trials for Evaluation of Serum Level of Insulin Like Growth Factor 1

Relation Between Serum IGF-1 & BMI In Acne Vulgaris

Start date: April 1, 2023
Phase:
Study type: Observational

cross-sectional study in which participants will be recruited at dermatology & Andrology out-patient clinics in Assuit university hospital, Egypt after patients examination by dermatologists & obtaining an informed consent

NCT ID: NCT05296460 Not yet recruiting - Acne Vulgaris Clinical Trials

DAPSONE GEL7.5%Versus Trichloroacetic Acid 20% ON ACNE VULGARIS

Start date: September 1, 2022
Phase: Phase 4
Study type: Interventional

Acne vulgaris, a chronic inflammatory skin disorder, is one of the most prevalent diseases that effects more than 80% of the population worldwide . A variety of factors such as genetics, hormones, infections, as well as environmental factors have been identified as the causes of acne development . Acne usually generates as a result of blockage in the pilosebaceous unit (including hair follicle, hair shaft, and sebaceous gland) due to the over-produced sebum by sebaceous gland, which further triggers the excessive proliferation of the bacterium Propionibacterium acnes (P. Acnes).

NCT ID: NCT05271487 Not yet recruiting - Acne Vulgaris Clinical Trials

A Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome

Start date: March 7, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze changes in acne and changes in the gut and skin microbiome with the use of a multi-step botanical skin care regimen in those with mild to moderate acne.

NCT ID: NCT05269641 Recruiting - Acne Vulgaris Clinical Trials

Almond Supplementation on Mild to Moderate Acne

Start date: February 28, 2022
Phase: N/A
Study type: Interventional

This study will assess the effect of almond supplementation on acne and on gut health.